HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
September 08, 2021 06:30 ET
|
HUTCHMED (China) Limited
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”)...
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference
September 07, 2021 04:30 ET
|
HUTCHMED (China) Limited
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates...
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
September 06, 2021 02:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 06, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Company’s ordinary...
HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer
August 25, 2021 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of...
HUTCHMED Selected as Constituent of Certain Hang Seng Indexes
August 22, 2021 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 22, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been...
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
August 08, 2021 20:00 ET
|
HUTCHMED (China) Limited
Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and...
HUTCHMED Reports 2021 Interim Results and Provides Business Updates
July 28, 2021 07:00 ET
|
HUTCHMED (China) Limited
ELUNATE® in-market sales1 rose 186%, reflecting impact of in-house sales force Received 1st approval in China for ORPATHYS® and 2nd approval in China for SULANDA® U.S. and E.U. applications for...
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
July 27, 2021 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG, SHANGHAI, FLORHAM PARK, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq: AZN)...
Stabilizing Actions and End of Stabilization Period in connection with the Global Offering
July 23, 2021 07:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that the...
HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency
July 15, 2021 20:00 ET
|
HUTCHMED (China) Limited
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in...